The emergence of glucagon-like peptide-1 receptor agonists (GLP-1RAs), including tirzepatide (Mounjaro), has revolutionized the management of type 2 diabetes mellitus and obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.